文献速递糖尿病

血浆抗坏血酸与胰岛自身免疫及1型糖尿病风险:TEDDY研究

Plasma ascorbic acid and the risk of islet autoimmunity and type 1 diabetes: the TEDDY study.
PubMed 文献 · Diabetologia · 2019-11-14

在TEDDY队列中采用巢式病例对照设计,分析儿童血浆抗坏血酸与胰岛自身免疫(350例/974对照)及1型糖尿病(102例/282对照)风险的关联。结果显示血浆抗坏血酸每升高1 mg/l与胰岛自身免疫风险降低相关(调整OR 0.96,95%CI 0.92–0.99),但与1型糖尿病风险无显著关联;SLC2A2 rs5400 SNP与1型糖尿病风险增加相关。

要点

  • 血浆抗坏血酸每升高1 mg/l,胰岛自身免疫风险调整OR为0.96(95%CI 0.92–0.99)。
  • 血浆抗坏血酸与1型糖尿病风险无显著关联(OR 0.93,95%CI 0.86–1.02)。
  • SLC2A2 rs5400 SNP与1型糖尿病风险增加相关(OR 1.77,95%CI 1.12–2.80)。

核心结论

  • 较高的儿童期血浆抗坏血酸水平可能与遗传高危儿童胰岛自身免疫风险降低相关。
  • 血浆抗坏血酸与1型糖尿病风险无显著关联。
  • SLC2A2 rs5400 SNP与1型糖尿病风险增加独立相关。

研究设计与样本

  • 在TEDDY国际多中心观察性研究中采用风险集抽样巢式病例对照设计。
  • 胰岛自身免疫分析纳入350例病例和974例对照,1型糖尿病分析纳入102例病例和282例对照。
  • 对照按1型糖尿病家族史、临床中心和性别匹配,并调整HLA基因型和人群分层。
  • 血浆抗坏血酸在6月龄、12月龄及此后每年至6岁测量,维生素C转运基因SNP用ImmunoChip定制芯片基因分型。

主要发现

  • 对照儿童血浆抗坏血酸均值±SD为10.76±3.54 mg/l。
  • 血浆抗坏血酸每升高1 mg/l,胰岛自身免疫风险调整OR为0.96(95%CI 0.92–0.99)。
  • 以胰岛素自身抗体起始的胰岛自身免疫风险调整OR为0.94(95%CI 0.88–0.99)。
  • 血浆抗坏血酸与1型糖尿病风险无显著关联(OR 0.93,95%CI 0.86–1.02)。
  • SLC2A2 rs5400 SNP与1型糖尿病风险增加相关(OR 1.77,95%CI 1.12–2.80),独立于血浆抗坏血酸(OR 0.92,95%CI 0.84–1.00)。

临床怎么用

  • 对1型糖尿病遗传高危儿童,监测血浆抗坏血酸水平可能有助于评估胰岛自身免疫风险。
  • SLC2A2 rs5400 SNP可能作为1型糖尿病风险分层的候选遗传标记。
  • 目前证据尚不足以推荐补充维生素C来预防1型糖尿病。

局限性

  • 作者指出需进一步研究确认这些发现。
  • 研究为观察性设计,不能证明因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: We studied the association of plasma ascorbic acid with the risk of developing islet autoimmunity and type 1 diabetes and examined whether SNPs in vitamin C transport genes modify these associations. Furthermore, we aimed to determine whether the SNPs themselves are associated with the risk of islet autoimmunity or type 1 diabetes. METHODS: We used a risk set sampled nested case-control design within an ongoing international multicentre observational study: The Environmental Determinants of Diabetes in the Young (TEDDY). The TEDDY study followed children with increased genetic risk from birth to endpoints of islet autoantibodies (350 cases, 974 controls) and type 1 diabetes (102 cases, 282 controls) in six clinical centres. Control participants were matched for family history of type 1 diabetes, clinical centre and sex. Plasma ascorbic acid concentration was measured at ages 6 and 12 months and then annually up to age 6 years. SNPs in vitamin C transport genes were genotyped using the ImmunoChip custom microarray. Comparisons were adjusted for HLA genotypes and for background population stratification. RESULTS: Childhood plasma ascorbic acid (mean ± SD 10.76 ± 3.54 mg/l in controls) was inversely associated with islet autoimmunity risk (adjusted OR 0.96 [95% CI 0.92, 0.99] per +1 mg/l), particularly islet autoimmunity, starting with insulin autoantibodies (OR 0.94 [95% CI 0.88, 0.99]), but not with type 1 diabetes risk (OR 0.93 [95% Cl 0.86, 1.02]). The SLC2A2 rs5400 SNP was associated with increased risk of type 1 diabetes (OR 1.77 [95% CI 1.12, 2.80]), independent of plasma ascorbic acid (OR 0.92 [95% CI 0.84, 1.00]). CONCLUSIONS/INTERPRETATION: Higher plasma ascorbic acid levels may protect against islet autoimmunity in children genetically at risk for type 1 diabetes. Further studies are warranted to confirm these findings. DATA AVAILABILITY: The datasets generated and analysed during the current study will be made available in the NIDDK Central Repository at https://www.niddkrepository.org/studies/teddy.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Mattila M, Erlund I, Lee HS, et al. Plasma ascorbic acid and the risk of islet autoimmunity and type 1 diabetes: the TEDDY study. Diabetologia. 2019. PMID: 31728565. doi:10.1007/s00125-019-05028-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。